189 related articles for article (PubMed ID: 29463131)
1. Rational design for cervical cancer therapeutics: cellular and non-cellular based strategies on the horizon for recurrent, metastatic or refractory cervical cancer.
Wolford JE; Tewari KS
Expert Opin Drug Discov; 2018 May; 13(5):445-457. PubMed ID: 29463131
[TBL] [Abstract][Full Text] [Related]
2. New strategies in advanced cervical cancer: from angiogenesis blockade to immunotherapy.
Tewari KS; Monk BJ
Clin Cancer Res; 2014 Nov; 20(21):5349-58. PubMed ID: 25104084
[TBL] [Abstract][Full Text] [Related]
3. [Preventive vaccines and immunotherapy clinical trials against cervical cancer].
Valdespino-Gómez VM
Cir Cir; 2005; 73(1):57-69. PubMed ID: 15888272
[TBL] [Abstract][Full Text] [Related]
4. Multimodality imaging of locally recurrent and metastatic cervical cancer: emphasis on histology, prognosis, and management.
Park KJ; Braschi-Amirfarzan M; DiPiro PJ; Giardino AA; Jagannathan JP; Howard SA; Shinagare AB; Krajewski KM
Abdom Radiol (NY); 2016 Dec; 41(12):2496-2508. PubMed ID: 27357415
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer.
Burger RA; Monk BJ; Kurosaki T; Anton-Culver H; Vasilev SA; Berman ML; Wilczynski SP
J Natl Cancer Inst; 1996 Oct; 88(19):1361-8. PubMed ID: 8827013
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy and targeted therapy for cervical cancer: an update.
Menderes G; Black J; Schwab CL; Santin AD
Expert Rev Anticancer Ther; 2016; 16(1):83-98. PubMed ID: 26568261
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of current and emerging treatments for cervical cancer.
Duenas-Gonzalez A; Gonzalez-Fierro A
Expert Opin Drug Metab Toxicol; 2019 Aug; 15(8):671-682. PubMed ID: 31340683
[No Abstract] [Full Text] [Related]
8. Persistence of HPV after radio-chemotherapy in locally advanced cervical cancer.
Badaracco G; Savarese A; Micheli A; Rizzo C; Paolini F; Carosi M; Cutillo G; Vizza E; Arcangeli G; Venuti A
Oncol Rep; 2010 Apr; 23(4):1093-9. PubMed ID: 20204296
[TBL] [Abstract][Full Text] [Related]
9. Management Strategies for Recurrent Endometrial Cancer.
Connor EV; Rose PG
Expert Rev Anticancer Ther; 2018 Sep; 18(9):873-885. PubMed ID: 29972650
[TBL] [Abstract][Full Text] [Related]
10. HPV: Molecular pathways and targets.
Gupta S; Kumar P; Das BC
Curr Probl Cancer; 2018; 42(2):161-174. PubMed ID: 29706467
[TBL] [Abstract][Full Text] [Related]
11. Persistent human papillomavirus DNA is associated with local recurrence after radiotherapy of uterine cervical cancer.
Song YJ; Kim JY; Lee SK; Lim HS; Lim MC; Seo SS; Kang S; Lee DO; Park SY
Int J Cancer; 2011 Aug; 129(4):896-902. PubMed ID: 21064095
[TBL] [Abstract][Full Text] [Related]
12. Influence of HPV type on prognosis in patients diagnosed with invasive cervical cancer.
Cuschieri K; Brewster DH; Graham C; Nicoll S; Williams AR; Murray GI; Millan D; Johannessen I; Hardie A; Cubie HA
Int J Cancer; 2014 Dec; 135(11):2721-6. PubMed ID: 24740764
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for cervical cancer: Can it do another lung cancer?
Ramanathan P; Dhandapani H; Jayakumar H; Seetharaman A; Thangarajan R
Curr Probl Cancer; 2018; 42(2):148-160. PubMed ID: 29500076
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research.
Lee SJ; Yang A; Wu TC; Hung CF
J Gynecol Oncol; 2016 Sep; 27(5):e51. PubMed ID: 27329199
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of pre-treatment human papilloma virus DNA status in cervical cancer.
Chong GO; Lee YH; Han HS; Lee HJ; Park JY; Hong DG; Lee YS; Cho YL
Gynecol Oncol; 2018 Jan; 148(1):97-102. PubMed ID: 29153540
[TBL] [Abstract][Full Text] [Related]
16. Pharmacotherapy for the treatment of recurrent cervical cancer: an update of the literature.
D'Oria O; Bogani G; Cuccu I; D'Auge TG; Di Donato V; Caserta D; Giannini A
Expert Opin Pharmacother; 2024; 25(1):55-65. PubMed ID: 38159033
[TBL] [Abstract][Full Text] [Related]
17. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review.
Boussios S; Seraj E; Zarkavelis G; Petrakis D; Kollas A; Kafantari A; Assi A; Tatsi K; Pavlidis N; Pentheroudakis G
Crit Rev Oncol Hematol; 2016 Dec; 108():164-174. PubMed ID: 27931835
[TBL] [Abstract][Full Text] [Related]
18. Breaking the DNA damage response to improve cervical cancer treatment.
Wieringa HW; van der Zee AG; de Vries EG; van Vugt MA
Cancer Treat Rev; 2016 Jan; 42():30-40. PubMed ID: 26643553
[TBL] [Abstract][Full Text] [Related]
19. Natural history of human papillomavirus infections, cytologic and histologic abnormalities, and cancer.
Wheeler CM
Obstet Gynecol Clin North Am; 2008 Dec; 35(4):519-36; vii. PubMed ID: 19061814
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus 16-positive uterine cervical squamous cell carcinoma with coinfection with human papillomavirus 34 has a lower incidence in lymph node metastasis than that without coinfection with human papillomavirus 34.
Michimata R; Watari H; Tomaru U; Sakuragi N; Ishizu A
Pathobiology; 2013; 80(5):259-64. PubMed ID: 23689419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
